[go: up one dir, main page]

WO1998039436A3 - Fibroblast growth factor mutein compositions and methods of use therefor - Google Patents

Fibroblast growth factor mutein compositions and methods of use therefor Download PDF

Info

Publication number
WO1998039436A3
WO1998039436A3 PCT/JP1998/000878 JP9800878W WO9839436A3 WO 1998039436 A3 WO1998039436 A3 WO 1998039436A3 JP 9800878 W JP9800878 W JP 9800878W WO 9839436 A3 WO9839436 A3 WO 9839436A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
growth factor
fibroblast growth
fgf
use therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1998/000878
Other languages
French (fr)
Other versions
WO1998039436A2 (en
Inventor
Hengyi Zhu
Ramnarayan Kalyanaraman
Takatoshi Kawai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of WO1998039436A2 publication Critical patent/WO1998039436A2/en
Publication of WO1998039436A3 publication Critical patent/WO1998039436A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Isolated DNA molecules that encode fibroblast growth factor (FGF) mutein polypeptides and the encoded FGF muteins are provided. The FGF muteins exhibit reduced receptor binding activity, but retain the ability to bind to heparin. Methods for treating heparin-related disorders by administering a therapeutically effective amount of an FGF mutein are also provided.
PCT/JP1998/000878 1997-03-03 1998-03-03 Fibroblast growth factor mutein compositions and methods of use therefor Ceased WO1998039436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4078597P 1997-03-03 1997-03-03
US60/040,785 1997-03-03

Publications (2)

Publication Number Publication Date
WO1998039436A2 WO1998039436A2 (en) 1998-09-11
WO1998039436A3 true WO1998039436A3 (en) 1999-01-14

Family

ID=21912937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/000878 Ceased WO1998039436A2 (en) 1997-03-03 1998-03-03 Fibroblast growth factor mutein compositions and methods of use therefor

Country Status (1)

Country Link
WO (1) WO1998039436A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020189A (en) 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
US7252818B2 (en) 1998-07-24 2007-08-07 Cardiovascular Biotherapeutics, Inc. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
AU2001288256B2 (en) * 2000-08-15 2006-03-30 New Technologies Holdings Pte Ltd A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022369A1 (en) * 1994-10-13 1996-07-25 Amgen Inc. Analogs of acidic fibroblast growth factor having enhanced stability and biological activity
WO1996038167A1 (en) * 1995-05-31 1996-12-05 Osteosa, Inc. Use of fibroblast growth factors to stimulate bone growth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022369A1 (en) * 1994-10-13 1996-07-25 Amgen Inc. Analogs of acidic fibroblast growth factor having enhanced stability and biological activity
WO1996038167A1 (en) * 1995-05-31 1996-12-05 Osteosa, Inc. Use of fibroblast growth factors to stimulate bone growth

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS, W.H., ET AL.: "possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic Fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", THE JOURNAL OF CELL BIOLOGY, vol. 111, November 1990 (1990-11-01), pages 2129 - 2138, XP002074068 *
SPRINGER, B.A., ET AL.: "identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 43, October 1994 (1994-10-01), pages 26879 - 26884, XP002073992 *
WANG W -P ET AL: "CLONING OF THE GENE CODING FOR HUMAN CLASS 1 HEPARIN-BINDING GROWTH FACTOR AND ITS EXPRESSION IN FETAL TISSUES", MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 6, June 1989 (1989-06-01), pages 2387 - 2395, XP000039606 *
ZHU, H., ET AL.: "Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 37, September 1995 (1995-09-01), pages 21869 - 21874, XP002073993 *

Also Published As

Publication number Publication date
WO1998039436A2 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
WO2002030358A3 (en) Modulation of ccr4 function
EP2290079A3 (en) Neurotrophic factors
CA2269083A1 (en) Novel fgf homologs
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
WO1992013553A3 (en) Method and agents for promoting wound healing
CA2296769A1 (en) Modified dorsal tissue affecting factor and compositions
TR199802421T2 (en) Substances that regulate tissue regeneration.
MX9604985A (en) Cardiotrophin and uses therefor.
EP0637450A3 (en) Composition for revitalizing scar tissue.
WO2000025725A3 (en) Functional antagonists of hedgehog activity
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO1999055861A3 (en) Fibroblast growth factor mutein compositions and methods of use therefor
AU1934995A (en) Receptor specific atrial natriuretic peptides
CA2233009A1 (en) Composition for improving pancreatic function
FI972703L (en) Recombinant IL-5 antagonists useful in treating IL-5-related diseases
WO2000053749A3 (en) Vascular adhesion molecules and modulation of their function
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
WO1998039436A3 (en) Fibroblast growth factor mutein compositions and methods of use therefor
WO1999064598A3 (en) Novel insulin analogs with enhanced zinc binding
EP0811687A3 (en) Polypeptides having l-asparaginase activity
WO1997003701A3 (en) Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
AU9487698A (en) Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538364

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase